UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1428-2
Program Prior Authorization/Notification
Medication Zilbrysq® (zilucoplan)
P&T Approval Date 1/2024, 1/2025
Effective Date 4/1/2025
1. Background:
Zilbrysq (zilucoplan) is a complement inhibitor indicated for the treatment of generalized
myasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody
positive.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Zilbrysq will be approved based on all of the following criteria:
a. Diagnosis of generalized myasthenia gravis (gMG)
-AND-
b. Positive serologic test for anti-AChR antibodies
-AND-
c. Patient is not receiving Zilbrysq in combination with another complement inhibitor
[e.g., Soliris (eculizumab), Ultomiris (ravulizumab-cwvz)] or a neonatal Fc receptor
blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab),
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]
Authorization will be issued for 12 months.
B. Reauthorization
1. Zilbrysq will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Zilbrysq therapy
-AND-
b. Patient is not receiving Zilbrysq in combination with another complement inhibitor
[e.g., Soliris (eculizumab), Ultomiris (ravulizumab-cwvz)] or a neonatal Fc receptor
blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab),
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services Inc.
1
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may also be in place.
4. References:
1. Zilbrysq [package insert], Smyrna, GA: UCB, Inc.; April 2024.
Program Prior Authorization/Notification - Zilbrysq® (zilucoplan)
Change Control
1/2024 New program.
1/2025 Annual review. Updated listing of examples of complement inhibitors and
neonatal Fc receptor blockers without change to clinical intent. Updated
reference.
© 2025 UnitedHealthcare Services Inc.
2